[go: up one dir, main page]

CO5680418A2 - Modificaciones estables de maleato acido de tegaserod - Google Patents

Modificaciones estables de maleato acido de tegaserod

Info

Publication number
CO5680418A2
CO5680418A2 CO06016978A CO06016978A CO5680418A2 CO 5680418 A2 CO5680418 A2 CO 5680418A2 CO 06016978 A CO06016978 A CO 06016978A CO 06016978 A CO06016978 A CO 06016978A CO 5680418 A2 CO5680418 A2 CO 5680418A2
Authority
CO
Colombia
Prior art keywords
tegaserod
acid maleate
stable modifications
maleate
stable
Prior art date
Application number
CO06016978A
Other languages
English (en)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5680418(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5680418A2 publication Critical patent/CO5680418A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

1.- Una modificación cristalina A del maleato ácido de tegaserod.2.- Una modificación cristalina A del maleato ácido de tegaserod, caracterizada porque comprende la siguiente estructura cristalina característica, determinada por medio de análisis en un solo cristal, con rayos X: Sistema cristalino triclínico Grupo espacial P-1 a,Å 8.640 b,Å 15.800 c,Å 17.472 aÅ 68.67 ßÅ 88.10 ?Å 88.02 V,Å3 3 2232 Z 4 D(calc.), g/cm3 1.242.
CO06016978A 2003-07-24 2006-02-21 Modificaciones estables de maleato acido de tegaserod CO5680418A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
CO5680418A2 true CO5680418A2 (es) 2006-09-29

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06016978A CO5680418A2 (es) 2003-07-24 2006-02-21 Modificaciones estables de maleato acido de tegaserod

Country Status (24)

Country Link
US (1) US20070112056A1 (es)
EP (2) EP1651601A1 (es)
JP (1) JP2006528609A (es)
KR (1) KR20060040710A (es)
CN (1) CN1826318A (es)
AR (1) AR045081A1 (es)
AU (1) AU2004263285A1 (es)
BR (1) BRPI0412830A (es)
CA (1) CA2532351A1 (es)
CO (1) CO5680418A2 (es)
EC (1) ECSP066306A (es)
IL (1) IL172914A0 (es)
IS (1) IS8321A (es)
MA (1) MA27935A1 (es)
MX (1) MXPA06000917A (es)
MY (1) MY137386A (es)
NO (1) NO20060915L (es)
NZ (1) NZ544596A (es)
PE (1) PE20050253A1 (es)
RU (1) RU2349585C2 (es)
SG (1) SG144944A1 (es)
TN (1) TNSN06024A1 (es)
TW (1) TW200510302A (es)
WO (1) WO2005014544A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582090A1 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
RU2007132704A (ru) * 2005-01-31 2009-03-10 Новартис АГ (CH) Органические соединения
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate
WO2007119109A2 (en) * 2005-10-06 2007-10-25 Medichem, S.A. Processes for preparing tegaserod maleate and pharmaceutical compositions containing it
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod maleate free of iodide
EP1956002A1 (en) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. New tegaserod maleate polymorphs and process for their preparation
CA2687209A1 (en) * 2007-05-17 2008-11-27 Generics (Uk) Limited Process for the preparation of form a of tegaserod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
CN1165293C (zh) * 1998-08-21 2004-09-08 诺瓦提斯公司 5ht4激动剂或拮抗剂的新型口服制剂
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate

Also Published As

Publication number Publication date
RU2006105481A (ru) 2007-09-20
NO20060915L (no) 2006-04-24
MY137386A (en) 2009-01-30
TW200510302A (en) 2005-03-16
JP2006528609A (ja) 2006-12-21
CA2532351A1 (en) 2005-02-17
WO2005014544A1 (en) 2005-02-17
SG144944A1 (en) 2008-08-28
EP1880992A1 (en) 2008-01-23
RU2349585C2 (ru) 2009-03-20
AR045081A1 (es) 2005-10-12
BRPI0412830A (pt) 2006-09-26
ECSP066306A (es) 2006-07-28
TNSN06024A1 (en) 2007-10-03
IS8321A (is) 2006-02-22
MXPA06000917A (es) 2006-03-30
KR20060040710A (ko) 2006-05-10
CN1826318A (zh) 2006-08-30
EP1651601A1 (en) 2006-05-03
MA27935A1 (fr) 2006-06-01
IL172914A0 (en) 2006-06-11
NZ544596A (en) 2009-01-31
PE20050253A1 (es) 2005-06-03
US20070112056A1 (en) 2007-05-17
AU2004263285A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
CO5680418A2 (es) Modificaciones estables de maleato acido de tegaserod
CY1109760T1 (el) Παραγωγα ινδολης-3-θειου
TW200407305A (en) Novel compounds
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
HK1047098A1 (en) Tri-aryl acid derivatives as ppar receptor ligands.
EA200601773A1 (ru) Тетраазабензо[е]азуленовые производные и их аналоги
NZ235155A (en) Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
AU5860790A (en) Substituted quinazolinones as angiotensin ii antagonists
NO942817L (no) Tricykliske benzazepiner som rasopressin-antagonister
BRPI0414592A (pt) antagonistas de receptores de trombina
CA2511976A1 (en) System to produce drinking water
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
TNSN04138A1 (fr) Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique
TR200100422T2 (tr) Primetanil ihtiva etmekte olan süspansiyon konsantre formülasyon
SG144140A1 (en) Emulsifying systems containing azetidine derivatives
DK0871612T3 (da) Kondenserede isoindoloner som proteinkinase C-inhibitorer
NO20044608L (no) Fremgangsmate for a fremstille konjugert linolsyre
ATE232081T1 (de) Orale zusammensetzung enthaltend perlit
FR2796641B1 (fr) Nouveau procede de preparation de composes benzoperhydroisoindole
DE50305762D1 (de) 3,3,4,4-tetrafluorcyclopentanverbindungen als komponenten flüssigkristalliner medien
EA200000736A1 (ru) Фармацевтические композиции
DE3781368D1 (de) Granulierte trikalziumphosphat-zusammensetzungen, geeignet zur tablettierung durch direkte kompression.
GB9906458D0 (en) Compound

Legal Events

Date Code Title Description
FC Application refused